Stockscreener 앱 받기
1.01
1.08%
-0.011
시장 영업 전:
1.01
전일 마감가:
$1.021
열려 있는:
$0.99
하루 거래량:
77,166
Relative Volume:
0.45
시가총액:
$32.94M
수익:
-
순이익/손실:
-
주가수익비율:
-2.9015
EPS:
-0.3481
순현금흐름:
-
1주 성능:
+32.81%
1개월 성능:
+32.89%
6개월 성능:
-18.55%
1년 성능:
-65.76%
1일 변동 폭
$0.98
$1.0846
1주일 범위
$0.76
$1.24
52주 변동 폭
$0.5714
$3.70
Akari Therapeutics Plc Adr Stock (AKTX) Company Profile
명칭
Akari Therapeutics Plc Adr
전화
(646) 350-0702
주소
22 BOSTON WHARF ROAD, BOSTON
AKTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AKTX
Akari Therapeutics Plc Adr
|
1.01 | 33.30M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.64 | 101.35B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.00 | 58.66B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
562.27 | 59.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
737.56 | 44.01B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
340.70 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
Akari Therapeutics Plc Adr Stock (AKTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-18 | 개시 | Maxim Group | Buy |
| 2019-01-04 | 업그레이드 | B. Riley FBR | Neutral → Buy |
| 2018-02-08 | 개시 | B. Riley FBR, Inc. | Neutral |
| 2017-09-22 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2017-05-31 | 업그레이드 | Chardan Capital Markets | Sell → Neutral |
| 2017-04-17 | 재확인 | Chardan Capital Markets | Sell |
| 2016-07-11 | 개시 | Chardan Capital Markets | Sell |
모두보기
Akari Therapeutics Plc Adr 주식(AKTX)의 최신 뉴스
Stocks Moving Premarket: PEPG, WOK, ICU, And Other Gainers & Losers - RTTNews
Akari’s ADC payload shows promise against resistant prostate cancer By Investing.com - Investing.com South Africa
Akari’s ADC payload shows promise against resistant prostate cancer - Investing.com India
First Potential Treatment for AR-V7 Driven Prostate Cancer: Akari's PH1 Shows Dual Action in Studies - Stock Titan
Can momentum traders help lift Tripadvisor Inc.2025 Pullback Review & Verified Momentum Watchlists - newser.com
Analyzing PRA Group Inc. with risk reward ratio chartsJuly 2025 Big Picture & Weekly Top Gainers Alerts - newser.com
Institutional scanner results for ANSYS Inc.Entry Point & Verified Technical Trade Signals - newser.com
Does SRTY fit your quant trading modelPortfolio Gains Report & Stock Timing and Entry Methods - newser.com
Akari Therapeutics files patent for novel cancer treatment approach By Investing.com - Investing.com South Africa
Akari Therapeutics files patent for novel cancer treatment approach - Investing.com
Revolutionary Spliceosome Cancer Treatment: Akari Files Patent for First-in-Class ADC Platform Technology - Stock Titan
Is BSIIU stock reversal real or fake2025 Market Overview & Verified Swing Trading Watchlists - newser.com
Security Solutions Inc.2025 Market Outlook & Smart Money Movement Tracker - newser.com
Applying big data sentiment scoring on HLITJuly 2025 Recap & Free Technical Pattern Based Buy Signals - newser.com
Novel ADC Developer Akari Therapeutics to Showcase Pipeline at Major Healthcare Conference - Stock Titan
Next-Gen Cancer Drug Developer Akari Therapeutics Showcases Novel IO-Payload ADC Platform - Stock Titan
Advanced analytics toolkit walkthrough for Educational Development CorporationShare Buyback & Free Expert Approved Momentum Trade Ideas - Newser
What high frequency data says about MGTXOil Prices & Free Technical Confirmation Trade Alerts - Newser
Using AI based signals to follow BWXT2025 Market Outlook & Fast Entry and Exit Trade Plans - Newser
Analyzing recovery setups for Guardian Pharmacy Services Inc. investorsMarket Volume Report & Weekly High Return Stock Forecasts - Newser
Akari Therapeutics completes $2.8 million note offering and extends warrant terms - Investing.com
Today's SEC FilingsLatest 10-K, 10-Q, 8-K Forms - Stock Titan
Cancer Drug Developer Akari Therapeutics Showcases Pipeline at Webull Biotech Conference - Stock Titan
Is BACQR still worth holding after the dipEquity Market Return Forecast Model Update - Newser
Insider Stock Buying Reaches US$1.79m On Akari Therapeutics - Sahm
Akari Therapeutics Reveals Breakthrough Progress in Cancer-Fighting Drug Development - Stock Titan
Akari Therapeutics advances cancer-fighting ADC technology with PH1 payload - Investing.com India
Revolutionary Cancer Drug PH1 Targets KRAS, BRAF While Activating Immune System Against Tumors - Stock Titan
Akari Therapeutics CEO Shares Exclusive Insights on Next-Gen Cancer Drug Development Strategy - Stock Titan
INKT Stock Quote Price and Forecast - CNN
Akari Therapeutics shareholders approve equity plan increase and director elections - Investing.com
Akari Therapeutics Expands Global IP Portfolio: Key Patent Win for Cancer Drug Platform in India - Stock Titan
AKTX CEO buys 10,000 ADS at $1.20 in Form 4 insider filing - Stock Titan
Akari Therapeutics secures Indian patent for cancer drug payload - Investing.com India
Akari's Revolutionary Cancer Drug Technology Wins Key Patent in India's 2.08M Patient Market - Stock Titan
Oncology Deal Veteran Mark Kubik Joins Akari Therapeutics to Accelerate ADC Pipeline Growth - Stock Titan
Akari Therapeutics CEO Reveals Latest Oncology ADC Developments at Major Webull Investor Event - Stock Titan
Akari Therapeutics Reports Q1 2025 Financial Results - TipRanks
Akari Therapeutics appoints new head of oncology business By Investing.com - Investing.com India
Akari Therapeutics appoints new head of oncology business - Investing.com
Akari Therapeutics' New CEO Reveals Future Roadmap: Key Insights from First Leadership Address - Stock Titan
Akari Therapeutics Advances ADC Development Amid Financial Challenges - TipRanks
Akari Therapeutics Transforms: Next-Gen Cancer Drug Shows Promise Amid 2024 Results - Stock Titan
Akari Therapeutics names new CEO to drive cancer drug innovation - Investing.com India
Akari Therapeutics Appoints New CEO, Current CEO to Step Down - Investing.com
Akari Therapeutics secures $7.6 million in private placement - Investing.com
Acciones de Alibaba (BABA) caen tras medidas de Trump para frenar inversiones chinas en tecnología - Yahoo Finanzas
Citi reveló que Ecopetrol ha publicado la guía de sus resultados para el cuarto trimestre de 2024 - Yahoo Finanzas
Akari Therapeutics appoints new CEO and board member - Investing.com
Rob Bazemore Appointed to the Board of Directors of Akari Therapeutics - Stock Titan
Riesgos y oportunidades sobre el futuro de la cotización de YPF - Yahoo Finanzas
Akari Therapeutics Plc Adr (AKTX) 재무 분석
Akari Therapeutics Plc Adr (AKTX)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
2.36%
1.10%
자본화:
|
볼륨(24시간):